Green Digital Diabetes Waste Project

Florida State University

Status: Completed

Conditions: Diabetes Mellitus, Type 1; Diabetes Mellitus; Diabetes Mellitus, Type 2

Study type: Observational

Funder types: Other

Identifiers

NCT06071325

STUDY00004453

Details and patient eligibility

About

The purpose of this study is to determine how people with diabetes are disposing of various products and devices and at what rates so that better devices with less waste can be designed in the future.

Full description

The study aims to compare the amount of environmental waste that is generated during the management of diabetes of participants who are using a CGM and on multiple daily injection (MDI) or using an AID (automated insulin delivery) system. This study is expected to demonstrate which devices create the most waste and where opportunities exist to decrease diabetes device waste. We will collect data to describe both quantitatively (via daily survey) and qualitatively (via photography) the types of waste that are generated during the management of diabetes.

Enrollment: 49 patients

Sex: All

Ages: 18 to 120 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Person with diabetes (self-identified), either type 1 or type 2, who has been diagnosed at least 6 months earlier
• Age 18 years and above
• Use of a CGM
• Use of an insulin pump or on MDI
• Access to the Internet and e-mail
• Access to a smartphone with photographic capability
• Able and willing to provide informed consent

Exclusion criteria

• Failure to meet any of the inclusion criteria
• Any condition which, in the opinion of an investigator, would make the subject not qualified to participate in the study.
• Adults unable to consent
• Adults unable to speak English
• Individuals who are not yet adults (infants, children, teenagers)
• Pregnant women
• Prisoners
• Cognitively impaired adults

Trial design

49 participants in 2 patient groups

AID Group

Description:

We anticipate enrolling between 30 and 50 participants who will be recruited to participate in the Automated Insulin Delivery (AID) system study.

MDI + CGM Group

Description:

We anticipate that between 10 and 30 participants will be enrolled in the study and will be utilizing Multiple Daily Injections (MDI) therapy in conjunction with Continuous Glucose Monitoring (CGM). MDI therapy will be defined as administering three or more injections per day.